Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
DMRA compared with CBIO: revenue, margins and what each company keeps, and the suppliers and customers both name
DMRA
Damora Therapeutics, Inc.
Change
Mkt cap
Revenue
Revenue
CBIO
Crescent Biopharma, Inc.
Change
Mkt cap
Revenue
Revenue
vs
Compare
DMRA
Damora Therapeutics, Inc.
vs
CBIO
Crescent Biopharma, Inc.
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Revenue flow
Desk
News
Calendar
Saved
Search
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Price
rebased to 0%
1D
1W
1M
3M
YTD
1Y
5Y
1D
1W
1M
3M
YTD
1Y
5Y
DMRA, solid
CBIO, dashed
Supply-chain overlap
Revenue flow
DMRA: latest quarter not drawable. CBIO: latest quarter is a loss; flow not drawable.
Method
›
DMRA
Damora Therapeutics, Inc.
Change
21.61
▲
+0.05%
· post 22.10
Mkt cap
$1.4B
Revenue
—
CBIO
Crescent Biopharma, Inc.
Change
13.55
▲
+4.94%
· post 13.10
Closed
Nov 3 '26
Mkt cap
$479.5M
Revenue
$1M
Q1 FY26
vs
Compare
Closed
Nov 3 '26
DMRA
Damora Therapeutics, Inc.
vs
CBIO
Crescent Biopharma, Inc.
21.61
▲
+0.05%
post 22.10
Price
13.55
▲
+4.94%
post 13.10
$1.4B
Mkt cap
$479.5M
—
Revenue
$1M
Q1 FY26
Change
Change
DMRA
21.61
▲
+0.05%
vs
CBIO
13.55
▲
+4.94%
Closed
Nov 3 '26
Supply-chain overlap
direct ties · both sides
Sources
›
direct ties · both sides
Only DMRA
3
—
Paragon
unlisted
supplier
—
Pre-Acquisition Damora
unlisted
supplier
—
Bridge Medicines
unlisted
supplier
Shared
0
No shared counterparties.
Only CBIO
5
CRL
Charles River Laboratories
supplier
—
Paragon Therapeutics
unlisted
supplier
—
WuXi Biologics (Hong Kong)
unlisted
supplier
Role chip = supplier or customer
—
= no ticker (unlisted)
Source: SEC EDGAR
—
WuXi Biologics Ireland
unlisted
supplier
1 more · CBIO chain
›